ASCO: Lack of Benefit Seen for Indefinite-Duration Immunotherapy in NSCLC

TUESDAY, June 6, 2023 -- For patients with advanced non-small cell lung cancer (NSCLC), indefinite duration of immunotherapy treatment does not seem to offer benefits over fixed-duration therapy for two years, according to a study published online...